Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Business (Details)

v3.22.1
Organization and Nature of Business (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
segment
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Subsidiary, Sale of Stock [Line Items]      
Number of operating segments | segment 1    
Net loss $ 3,960,308 $ 3,056,033  
Net cash used in operating activities 2,656,017 $ 5,112,202  
Accumulated deficit $ 47,885,681   $ 43,925,373
Minimum      
Subsidiary, Sale of Stock [Line Items]      
period in which the company has to raise additional capital to complete clinical development 9 months    
Maximum      
Subsidiary, Sale of Stock [Line Items]      
period in which the company has to raise additional capital to complete clinical development 12 months